Spruce Biosciences (NASDAQ:SPRB) Stock Rating Upgraded by Wall Street Zen

Spruce Biosciences (NASDAQ:SPRB – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

SPRB has been the topic of several other research reports. Guggenheim restated a “buy” rating and issued a $104.00 target price (down from $123.00) on shares of Spruce Biosciences in a report on Monday, August 17th. The Goldman Sachs Group upgraded shares of Spruce Biosciences to an “overweight” rating in a research note on Thursday, August 13th. Citigroup reissued a “market outperform” rating on shares of Spruce Biosciences in a report on Thursday. Weiss Ratings raised Spruce Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 6th. Finally, Citizens Jmp set a $143.00 price objective on Spruce Biosciences in a research report on Thursday. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Spruce Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.22.

Check Out Our Latest Stock Analysis on SPRB

Spruce Biosciences Stock Performance

Spruce Biosciences stock opened at $43.31 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.83 and a quick ratio of 4.83. Spruce Biosciences has a one year low of $38.06 and a one year high of $127.90. The stock has a market capitalization of $124.30 million, a PE ratio of -1.28 and a beta of 3.57. The business’s fifty day moving average is $47.22 and its 200 day moving average is $54.29.

Spruce Biosciences (NASDAQ:SPRB – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($8.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.68) by ($2.83). On average, sell-side analysts predict that Spruce Biosciences will post -28.15 EPS for the current year.

Institutional Trading of Spruce Biosciences

Several institutional investors have recently made changes to their positions in the business. ADAR1 Capital Management LLC boosted its holdings in shares of Spruce Biosciences by 1.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 58,600 shares of the company’s stock valued at $3,830,000 after purchasing an additional 600 shares during the last quarter. SkyView Investment Advisors LLC bought a new stake in shares of Spruce Biosciences in the second quarter worth about $162,000. Pale Fire Capital SE purchased a new stake in shares of Spruce Biosciences in the second quarter worth about $206,000. Stempoint Capital LP purchased a new stake in shares of Spruce Biosciences in the first quarter worth about $416,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Spruce Biosciences in the second quarter worth about $366,000. Hedge funds and other institutional investors own 91.71% of the company’s stock.

About Spruce Biosciences

(Get Free Report)

Spruce Biosciences is a biotechnology company focused on developing treatments for rare endocrine disorders. The U.S.-based company has concentrated on conditions with limited treatment options and has advanced oral drug candidates through clinical development. Its lead investigational candidate, tildacerfont, is a corticotropin-releasing factor type 1 receptor antagonist that Spruce studied for congenital adrenal hyperplasia, a rare disorder affecting hormone production. The company also evaluated the candidate for other endocrine conditions, including polycystic ovary syndrome.

Featured Articles

Analyst Recommendations for Spruce Biosciences (NASDAQ:SPRB)

Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.